MX2016001179A - Tratamiento de esclerosis multiple por induccion de alemtuzumab seguido por terapia de laquinimod. - Google Patents
Tratamiento de esclerosis multiple por induccion de alemtuzumab seguido por terapia de laquinimod.Info
- Publication number
- MX2016001179A MX2016001179A MX2016001179A MX2016001179A MX2016001179A MX 2016001179 A MX2016001179 A MX 2016001179A MX 2016001179 A MX2016001179 A MX 2016001179A MX 2016001179 A MX2016001179 A MX 2016001179A MX 2016001179 A MX2016001179 A MX 2016001179A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- laquinimod
- subject
- multiple sclerosis
- treating
- Prior art date
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004577 laquinimod Drugs 0.000 title abstract 4
- 229960000548 alemtuzumab Drugs 0.000 title 1
- 230000006698 induction Effects 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 208000034189 Sclerosis Diseases 0.000 abstract 1
- 238000009093 first-line therapy Methods 0.000 abstract 1
- 238000009115 maintenance therapy Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a un método para el tratamiento de un sujeto afligido con esclerosis múltiple (MS) o que presenta un síndrome clínicamente aislado (CIS) que comprende administrar periódicamente al sujeto una cantidad de laquinimod, en donde el sujeto ha recibido una terapia de inducción del anticuerpo anti-CD52. Esta invención también proporciona un método para el tratamiento de un sujeto afligido con MS o que presenta un CIS que comprende a) administrar al sujeto una cantidad de un anticuerpo anti-CD52, seguido por b) administrar periódicamente al sujeto una cantidad de laquinimod. Esta invención también proporciona un envase que comprende laquinimod y un anticuerpo anti-CD52 y composiciones farmacéuticas que comprenden laquinimod o un anticuerpo anti-CD52 para tratar un sujeto afligido con MS o que presenta un CIS, en donde el anticuerpo anti-CD52 es para terapia de inducción y el laquinimod es para la terapia de mantenimiento. Esta invención proporciona además, laquinimod para uso como una terapia de mantenimiento en el tratamiento de un sujeto afligido con MS o que presenta un CIS, caracterizado porque el sujeto ha recibido una terapia de inducción del anticuerpo anti-CD52.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361861354P | 2013-08-01 | 2013-08-01 | |
| US201361920085P | 2013-12-23 | 2013-12-23 | |
| PCT/US2014/049220 WO2015017690A1 (en) | 2013-08-01 | 2014-07-31 | Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016001179A true MX2016001179A (es) | 2016-04-29 |
Family
ID=52432437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016001179A MX2016001179A (es) | 2013-08-01 | 2014-07-31 | Tratamiento de esclerosis multiple por induccion de alemtuzumab seguido por terapia de laquinimod. |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20160184428A1 (es) |
| EP (1) | EP3027187A4 (es) |
| CA (1) | CA2917600A1 (es) |
| HK (1) | HK1223854A1 (es) |
| IL (1) | IL243487A0 (es) |
| MX (1) | MX2016001179A (es) |
| WO (1) | WO2015017690A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200299399A1 (en) * | 2017-04-21 | 2020-09-24 | Genzyme Corporation | Treatment of Multiple Sclerosis with Anti-CD52 Antibodies |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014521659A (ja) * | 2011-07-28 | 2014-08-28 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療 |
-
2014
- 2014-07-31 MX MX2016001179A patent/MX2016001179A/es unknown
- 2014-07-31 CA CA2917600A patent/CA2917600A1/en active Pending
- 2014-07-31 EP EP14831822.3A patent/EP3027187A4/en not_active Withdrawn
- 2014-07-31 HK HK16112323.5A patent/HK1223854A1/zh unknown
- 2014-07-31 WO PCT/US2014/049220 patent/WO2015017690A1/en not_active Ceased
- 2014-07-31 US US14/909,042 patent/US20160184428A1/en not_active Abandoned
-
2016
- 2016-01-05 IL IL243487A patent/IL243487A0/en unknown
- 2016-06-22 US US15/190,027 patent/US20160296513A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015017690A1 (en) | 2015-02-05 |
| EP3027187A1 (en) | 2016-06-08 |
| US20160184428A1 (en) | 2016-06-30 |
| IL243487A0 (en) | 2016-02-29 |
| HK1223854A1 (zh) | 2017-08-11 |
| CA2917600A1 (en) | 2015-02-05 |
| US20160296513A1 (en) | 2016-10-13 |
| EP3027187A4 (en) | 2017-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015012156A (es) | Terapia de induccion de rituximab seguida por terapia de acetato de glatiramer. | |
| PH12015502075A1 (en) | Treatment of cataplexy | |
| MX2019002190A (es) | Uso de pridopidina para tratar distonías. | |
| UA116999C2 (uk) | Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить | |
| PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
| MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
| PH12016500140A1 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
| MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
| IN2014CH00395A (es) | ||
| MX2015000485A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina. | |
| MX382044B (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés. | |
| NZ730092A (en) | Use of cysteamine in treating infections caused by yeasts/moulds | |
| NZ707636A (en) | Ingenol-derived compounds that can be used for treating cancer | |
| PH12014502065A1 (en) | Vesicular formulations | |
| MX2016001179A (es) | Tratamiento de esclerosis multiple por induccion de alemtuzumab seguido por terapia de laquinimod. | |
| MX2016001177A (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina. | |
| GEAP202014778A (en) | Combination of trazodone and gabapentin for the treatmen | |
| IN2013MU03428A (es) | ||
| MX2016003763A (es) | Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple. | |
| IN2014KN02952A (es) | ||
| GB201114923D0 (en) | Immunogenic proteins and compositions | |
| IN2013MU03427A (es) | ||
| UA114811C2 (uk) | Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу | |
| MX2016008214A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y teriflunomida. | |
| NZ745950A (en) | Methods and compositions for treating multiple sclerosis and related disorders |